CCR4 | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | CCR4, CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099, K5-5, C-C motif chemokine receptor 4 | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 604836; MGI: 107824; HomoloGene: 21135; GeneCards: CCR4; OMA:CCR4 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
C-C chemokine receptor type 4 is a protein that in humans is encoded by the CCR4 gene.[5][6][7] CCR4 has also recently been designated CD194 (cluster of differentiation 194).
The protein encoded by this gene belongs to the G protein-coupled receptor family. It is a receptor for the following CC chemokines:
Chemokines are a group of small structurally related proteins that regulate cell trafficking of various types of leukocytes. The chemokines also play fundamental roles in the development, homeostasis, and function of the immune system, and they have effects on cells of the central nervous system as well as on endothelial cells involved in angiogenesis or angiostasis.[7]
CCR4 is a cell-surface protein and should not be confused with the unrelated carbon catabolite repression-negative on TATA-less (CCR4-Not), a nuclear protein complex that regulates gene expression.
Clinical significance
CCR4 is often expressed on leukemic cells in cutaneous T-cell lymphoma (CTCL).[10]
As a drug target
Mogamulizumab is a humanised monoclonal antibody targeted at CCR4 and is an investigational drug for CTCL.[10]
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000183813 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000047898 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Power CA, Meyer A, Nemeth K, Bacon KB, Hoogewerf AJ, Proudfoot AE, Wells TN (Sep 1995). "Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line". J Biol Chem. 270 (33): 19495–500. doi:10.1074/jbc.270.33.19495. PMID 7642634.
- ^ Samson M, Soularue P, Vassart G, Parmentier M (Feb 1997). "The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3". Genomics. 36 (3): 522–6. doi:10.1006/geno.1996.0498. PMID 8884276.
- ^ a b "Entrez Gene: CCR4 chemokine (C-C motif) receptor 4".
- ^ Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O (June 1997). "The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4". J. Biol. Chem. 272 (23): 15036–42. doi:10.1074/jbc.272.23.15036. PMID 9169480.
- ^ Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, Yoshie O, Gray PW (January 1998). "Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4". J. Biol. Chem. 273 (3): 1764–8. doi:10.1074/jbc.273.3.1764. PMID 9430724.
- ^ a b FDA grants priority review to mogamulizumab for cutaneous T-cell lymphoma Nov 2017
External links
- Human CCR4 genome location and CCR4 gene details page in the UCSC Genome Browser.
- CCR4+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- "Chemokine Receptors: CCR4". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-06-01. Retrieved 2008-11-25.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.